NYSE · CIK 0000943819 · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
ResMed Inc.
RMD chart by TradingView
PRICE HISTORY
LIVE · NYSERMD chart by TradingView
- REVENUE FY2025 ENDED JUN 2025
- $5.1B
- EBITDA
- $1.9B
- FREE CASH FLOW
- $1.7B
- EPS
- $9.51
- GROSS MARGIN
- 59.36%
- ROIC
- 25.86%
Q3 FY26ENDED MAR 2026HOVERDRAG ACROSS ANY CHART TO SCRUB ALL 24 · 40 QUARTERS SHOWNVALUATIONGROWTHPROFITABILITY & RETURNSCASH & CAPITALBALANCE SHEET
VALUATION
what you pay for a unit of the business7 CHARTS⤢
P / E RATIO (TTM)
21.5x
-15%21.5x77.4x
⤢
P / SALES (TTM)
5.9x
+22%4.5x11.6x
⤢
P / BOOK
5.0x
-4%5.0x12.8x
⤢
EV / EBITDA (TTM)
14.9x
-15%14.9x35.5x
⤢
EV / REVENUE (TTM)
5.7x
+15%4.5x11.7x
⤢
FCF YIELD (TTM)
5.36%
-0.1pp0.70%5.48%
⤢
DIVIDEND YIELD (TTM)
1.04%
-0.9pp0.60%2.03%
GROWTH
is the business getting bigger5 CHARTS⤢
REVENUE
$1.4B
+176%⤢
EBITDA (DERIVED)
$0.6B
+284%⤢
NET INCOME
$0.4B
+380%⤢
EPS (DILUTED)
$2.74
+365%⤢
REVENUE GROWTH YOY
10.81%
-3.7pp-0.09%29.20%
PROFITABILITY & RETURNS
what survives to the bottom, and what it earns on capital4 CHARTS⤢
FCF MARGIN
36.36%
+11.6pp-10.29%43.19%
⤢
RETURN ON CAPITAL
29.02%
+9.8pp12.71%29.02%
⤢
RETURN ON EQUITY (TTM)
23.41%
+2.6pp14.12%25.38%
MARGIN FUNNEL
every line is a share of the same revenue, so they read on one scale — the gaps are what each layer takes out, and net rises above operating when income arrives from outside the businessGROSS MARGIN62.25%
OPERATING MARGIN34.92%
NET MARGIN27.86%
FCF MARGIN36.36%
CASH & CAPITAL
where the money actually goes5 CHARTS⤢
FREE CASH FLOW
$0.5B
+305%⤢
STOCK-BASED COMP
$0.0B
+130%⤢
CAPITAL EXPENDITURE
$0.0B
+134%⤢
SHARES OUTSTANDING
0.15B
+3%⤢
DIVIDEND / SHARE
$0.60
+100%BALANCE SHEET
how much cushion there is3 CHARTS⤢
CASH & EQUIVALENTS
$1.7B
+127%⤢
TOTAL DEBT
$0.4B
-54%⤢
DEBT / EBITDA (TTM)
0.2x
-89%0.2x2.2x
OWNERSHIP
10 LARGEST HOLDERS · WHO OWNS THE FLOATINSTITUTIONS 69.91%INSIDERS 0.50%OTHER / RETAIL 29.59%1,377 INSTITUTIONAL FILERS
| HOLDER | % HELD | SHARES | VALUE | CHANGE |
|---|---|---|---|---|
| Blackrock Inc. | 8.34% | 12.1M | $2.56B | -2.1% |
| Vanguard Capital Management LLC | 6.53% | 9.5M | $2.01B | NEW |
| Vanguard Portfolio Management LLC | 5.42% | 7.9M | $1.67B | NEW |
| State Street Corporation | 4.58% | 6.6M | $1.41B | +0.3% |
| Geode Capital Management, LLC | 3.00% | 4.4M | $922.5M | +1.2% |
| Bank Of New York Mellon Corporation | 2.89% | 4.2M | $889.6M | -14.8% |
| Morgan Stanley | 1.85% | 2.7M | $569.4M | -7.1% |
| Invesco Ltd. | 1.35% | 2.0M | $414.7M | +0.2% |
| Northern Trust Corporation | 1.19% | 1.7M | $365.7M | -3.3% |
| First Trust Advisors LP | 1.06% | 1.5M | $325.9M | +1.3% |
AS OF 2026-03-31 · MOST RECENT 13F FILINGS
SOURCE → 10-K · 10-Q · 8-K / GUIDANCE · ALL FILINGS
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.